BRPI0921588A2 - vacinas antivirais com imunogenicidade celular aperfeiçoada - Google Patents
vacinas antivirais com imunogenicidade celular aperfeiçoadaInfo
- Publication number
- BRPI0921588A2 BRPI0921588A2 BRPI0921588A BRPI0921588A BRPI0921588A2 BR PI0921588 A2 BRPI0921588 A2 BR PI0921588A2 BR PI0921588 A BRPI0921588 A BR PI0921588A BR PI0921588 A BRPI0921588 A BR PI0921588A BR PI0921588 A2 BRPI0921588 A2 BR PI0921588A2
- Authority
- BR
- Brazil
- Prior art keywords
- improved cellular
- cellular immunogenicity
- antiviral vaccines
- vaccines
- antiviral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122021004758-8A BR122021004758B1 (pt) | 2008-11-18 | 2009-11-18 | Uso de um peptídeo viral otimizado, vacina e seu método de fabricação, vetor e kit |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11570308P | 2008-11-18 | 2008-11-18 | |
US61/115,703 | 2008-11-18 | ||
US15218409P | 2009-02-12 | 2009-02-12 | |
US61/152,184 | 2009-02-12 | ||
US24818809P | 2009-10-02 | 2009-10-02 | |
US61/248,188 | 2009-10-02 | ||
PCT/US2009/064999 WO2010059732A1 (en) | 2008-11-18 | 2009-11-18 | Antiviral vaccines with improved cellular immunogenicity |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0921588A2 true BRPI0921588A2 (pt) | 2017-06-06 |
BRPI0921588B1 BRPI0921588B1 (pt) | 2021-12-28 |
Family
ID=42198483
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122021004758-8A BR122021004758B1 (pt) | 2008-11-18 | 2009-11-18 | Uso de um peptídeo viral otimizado, vacina e seu método de fabricação, vetor e kit |
BRPI0921588-3A BRPI0921588B1 (pt) | 2008-11-18 | 2009-11-18 | Vacina compreendendo um polipeptídeo viral e seu método de preparação, kit e uso do polipeptídeo viral |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122021004758-8A BR122021004758B1 (pt) | 2008-11-18 | 2009-11-18 | Uso de um peptídeo viral otimizado, vacina e seu método de fabricação, vetor e kit |
Country Status (22)
Country | Link |
---|---|
US (5) | US9017691B2 (pt) |
EP (2) | EP2358757B1 (pt) |
JP (4) | JP5694945B2 (pt) |
CN (1) | CN102282175B (pt) |
AP (1) | AP3719A (pt) |
AU (1) | AU2009316629B2 (pt) |
BR (2) | BR122021004758B1 (pt) |
CY (1) | CY1121215T1 (pt) |
DK (1) | DK2358757T3 (pt) |
ES (1) | ES2699685T3 (pt) |
HK (1) | HK1164896A1 (pt) |
HR (1) | HRP20181776T1 (pt) |
HU (1) | HUE042397T2 (pt) |
IL (2) | IL212984A (pt) |
LT (1) | LT2358757T (pt) |
NZ (2) | NZ593598A (pt) |
PL (1) | PL2358757T3 (pt) |
PT (1) | PT2358757T (pt) |
SG (1) | SG10201408784SA (pt) |
SI (1) | SI2358757T1 (pt) |
WO (1) | WO2010059732A1 (pt) |
ZA (2) | ZA201104538B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201802130T4 (tr) | 2008-10-10 | 2018-03-21 | Beth Israel Deaconess Medical Ct Inc | Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı. |
HUE042397T2 (hu) | 2008-11-18 | 2019-06-28 | Beth Israel Deaconess Medical Ct Inc | Javított sejtes immunogenitású vírusellenes oltóanyagok |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
WO2014078688A2 (en) | 2012-11-16 | 2014-05-22 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
AU2014203886B2 (en) * | 2013-01-07 | 2017-11-02 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
EP3052518B1 (en) | 2013-10-04 | 2020-01-08 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
KR20230093536A (ko) | 2013-10-07 | 2023-06-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 어쥬번트로서 인터류킨-33을 갖는 백신 |
EP3058065B1 (en) * | 2013-10-16 | 2018-05-02 | New England Biolabs, Inc. | Reverse transcriptase with enhanced properties |
US9750801B2 (en) * | 2014-02-28 | 2017-09-05 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
PT3197489T (pt) | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana |
MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
WO2016069623A1 (en) * | 2014-10-27 | 2016-05-06 | Academia Sinica | Plant defense signaling peptides and applications thereof |
WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
CN108368157B (zh) * | 2015-12-15 | 2022-04-15 | 扬森疫苗与预防公司 | 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法 |
JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hivワクチン製剤 |
WO2018045267A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
CA3036959A1 (en) | 2016-09-15 | 2018-03-22 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
US11230572B2 (en) | 2016-10-17 | 2022-01-25 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
JP7272965B2 (ja) | 2017-06-15 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hiv抗原をコードするポックスウイルスベクターおよびその使用方法 |
CN110891601A (zh) | 2017-07-19 | 2020-03-17 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
WO2019226829A1 (en) | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
WO2020064621A1 (en) | 2018-09-25 | 2020-04-02 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン |
CN116033920A (zh) * | 2020-04-14 | 2023-04-28 | 加利福尼亚大学董事会 | 大序列泛冠状病毒疫苗组合物 |
AU2021270777A1 (en) | 2020-05-12 | 2022-11-10 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
AR124937A1 (es) | 2021-02-23 | 2023-05-24 | Janssen Vaccines & Prevention Bv | Mutación estabilizante de trímeros de proteínas de la envoltura del vih |
WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US20040101957A1 (en) * | 2001-09-14 | 2004-05-27 | Emini Emilio A. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications |
AU9456201A (en) * | 2000-09-15 | 2002-03-26 | Merck & Co Inc | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
EP1461077A4 (en) | 2001-11-07 | 2006-01-25 | Univ Duke | POLYVALENT IMMUNOGEN |
US7195768B2 (en) | 2001-11-07 | 2007-03-27 | Duke University | Polyvalent immunogen |
US7172761B2 (en) | 2001-11-07 | 2007-02-06 | Duke University | Polyvalent immunogen |
WO2003046137A2 (en) | 2001-11-27 | 2003-06-05 | Duke University | Hiv envelope v3-ccr5 binding site immunogen |
ES2310247T3 (es) | 2002-04-25 | 2009-01-01 | Crucell Holland B.V. | Vectores adenovirales estables y metodos de propagacion de los mismos. |
US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
US20050221493A1 (en) | 2002-12-04 | 2005-10-06 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
WO2005028625A2 (en) | 2003-09-17 | 2005-03-31 | Duke University | Consensus/ancestral immunogens |
WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
CA2583843C (en) | 2004-10-13 | 2010-09-21 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
NZ555907A (en) | 2004-11-16 | 2009-12-24 | Aeras Global Tb Vaccine Found | Multivalent vaccines comprising recombinant viral vectors |
US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
US8119140B2 (en) | 2005-08-23 | 2012-02-21 | Los Alamos Security, LLC | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
US20080279879A1 (en) * | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
CA2682206A1 (en) | 2007-03-27 | 2008-10-02 | The Regents Of The University Of California | Acute transmitted hiv envelope signatures |
WO2010042817A1 (en) * | 2008-10-10 | 2010-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of hiv mosaic envelope proteins to optimize t-cell responses against hiv envelope |
HUE042397T2 (hu) | 2008-11-18 | 2019-06-28 | Beth Israel Deaconess Medical Ct Inc | Javított sejtes immunogenitású vírusellenes oltóanyagok |
WO2010096561A1 (en) * | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
US9017961B2 (en) | 2012-03-05 | 2015-04-28 | E.I. Du Pont De Nemours And Company | Recombinant bacteria comprising novel sucrose transporters |
-
2009
- 2009-11-18 HU HUE09828172A patent/HUE042397T2/hu unknown
- 2009-11-18 CN CN200980154787.4A patent/CN102282175B/zh active Active
- 2009-11-18 EP EP09828172.8A patent/EP2358757B1/en active Active
- 2009-11-18 LT LTEP09828172.8T patent/LT2358757T/lt unknown
- 2009-11-18 AP AP2011005767A patent/AP3719A/en active
- 2009-11-18 ES ES09828172T patent/ES2699685T3/es active Active
- 2009-11-18 EP EP18191558.8A patent/EP3470437A1/en not_active Withdrawn
- 2009-11-18 AU AU2009316629A patent/AU2009316629B2/en not_active Ceased
- 2009-11-18 NZ NZ593598A patent/NZ593598A/xx unknown
- 2009-11-18 BR BR122021004758-8A patent/BR122021004758B1/pt active IP Right Grant
- 2009-11-18 JP JP2011537586A patent/JP5694945B2/ja active Active
- 2009-11-18 SG SG10201408784SA patent/SG10201408784SA/en unknown
- 2009-11-18 PL PL09828172T patent/PL2358757T3/pl unknown
- 2009-11-18 BR BRPI0921588-3A patent/BRPI0921588B1/pt active IP Right Grant
- 2009-11-18 SI SI200931885T patent/SI2358757T1/sl unknown
- 2009-11-18 US US13/130,018 patent/US9017691B2/en active Active
- 2009-11-18 NZ NZ60250409A patent/NZ602504A/en unknown
- 2009-11-18 DK DK09828172.8T patent/DK2358757T3/da active
- 2009-11-18 WO PCT/US2009/064999 patent/WO2010059732A1/en active Application Filing
- 2009-11-18 PT PT09828172T patent/PT2358757T/pt unknown
-
2011
- 2011-05-18 IL IL212984A patent/IL212984A/en active IP Right Grant
- 2011-06-20 ZA ZA2011/04538A patent/ZA201104538B/en unknown
-
2012
- 2012-06-05 HK HK12105453.5A patent/HK1164896A1/xx not_active IP Right Cessation
- 2012-07-04 ZA ZA2012/04999A patent/ZA201204999B/en unknown
-
2015
- 2015-02-05 JP JP2015021128A patent/JP6023233B2/ja not_active Expired - Fee Related
- 2015-02-26 US US14/632,869 patent/US9670253B2/en active Active
-
2016
- 2016-02-07 IL IL243991A patent/IL243991B/en active IP Right Grant
- 2016-10-06 JP JP2016198037A patent/JP6224197B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-17 US US15/489,220 patent/US10426831B2/en not_active Expired - Fee Related
- 2017-10-04 JP JP2017193941A patent/JP6368416B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-29 HR HRP20181776TT patent/HRP20181776T1/hr unknown
- 2018-12-10 CY CY20181101309T patent/CY1121215T1/el unknown
-
2019
- 2019-06-14 US US16/441,703 patent/US10772952B2/en active Active
-
2020
- 2020-09-10 US US16/948,257 patent/US11331386B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921588A2 (pt) | vacinas antivirais com imunogenicidade celular aperfeiçoada | |
DK2200646T3 (da) | RNA-Vacciner | |
DK2049559T3 (da) | Forbedrede HPV vacciner | |
BRPI0909770A2 (pt) | Vacina, e, kit | |
DK2437790T3 (da) | Konjugeringsfremgangsmåder | |
DK2114993T3 (da) | Vaccine | |
BRPI0911604A2 (pt) | vacinas de polipeptídeo de flagelina | |
BRPI0920630A2 (pt) | vacina combinada com pertússis acelular | |
FI20086253A0 (fi) | Sieniendoglukanaasit, niiden valmistus ja käyttö | |
BRPI0917205A2 (pt) | vacina polivalente | |
FI20086250A0 (fi) | Sieniendoglukanaasit, niiden valmistus ja käyttö | |
BRPI1005919A2 (pt) | composição imunogênica | |
FR2930208B1 (fr) | Appuie-tete escamotable. | |
GB0809441D0 (en) | Cellular ceramic plates with adapted physical properties | |
DE112008003895A5 (de) | Mobiles Heizgerät | |
BRPI0921578A2 (pt) | vacinas unitemporais | |
FI20086252A0 (fi) | Radiovastaanotin | |
FI20096164A0 (fi) | Telakäyttö, tela ja menetelmä | |
BRPI0918169A2 (pt) | entretela com células distanciadoras | |
BRPI0919102A2 (pt) | vacinas de salmonella não-tifóide | |
FR2946526B1 (fr) | Sterilet | |
ES1067115Y (es) | Cultivador extensible | |
ES1071157Y (es) | Manta | |
ES1068886Y (es) | Vaso | |
FIU20080010U0 (fi) | Langattomasti avattava lukko |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |